Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast® and Lanzor®) in healthy volunteers

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 51, Issue 2, 2001, Pages 153-157

  Dugger, H A ^a   Carlson, J D ^b   Henderson, William ^b   Erdmann, G R ^c   Alam, S Mahmood ^d   Dham, Ruwayda ^d  

^a Flemington Pharmaceutical Corp   (United States)

^b PRACS Institute Ltd   (United States)

^c PRACS Analytical Laboratory   (United States)

^d Gulf Pharmaceutical Industries   (United Arab Emirates)

Author keywords

Bioequivalence; High performance liquid chromatography; Julphar; Lansoprazole; Pharmacokinetics

Indexed keywords

LANFAST; LANSOPRAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; OMEPRAZOLE; THERAPEUTIC EQUIVALENCY;

EID: 0035104660     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(00)00152-1     Document Type: Article

References (25)

1. A distribution-free procedure for the statistical analysis of bioequivalence studies
2. Striving for standards in bioequivalence assessment: a review
3. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749
4. Effects of AG-1749 (lansoprazole) and its metabolites on acid secretion and experimental ulcers (in Japanese)
5. Lansoprazole, a novel benzimidazole proton pump inhibitor, its related compounds have selective activity against Helicobacter pylori
6. Lansoprazole - A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders
7. Lansoprazole - A review of its pharmacodynamic and pharmacokinetics properties and its therapeutic efficacy in acid-related disorders
8. Pharmacokinetics and absolute bioavailability of lansoprazole
9. Phase I study of lansoprazole (AG-1749) antiulcer agent. Capsule form (in Japanese)
10. The effect of food and antacids on lansoprazole absorption and distribution
11. Clinical pharmacokinetics of lansoprazole
12. Conference Report: Analytical method validation: Bioavailability, bioequivalence and pharmacokinetic studies
13. Use of confidence intervals in analysis of comparative bioavailability trials
14. Comparison of different methods of decision making in bioequivalence assessment
15. An exact confidence interval from untransformed data for the ratio of two formulation mean
16. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products
17. A new procedure for testing equivalence in comparative bioavailability and other clinical trials
18. of two one-sided tests procedure and the power approach for assessing the bioequivalence of average bioavailability